Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Eli Lilly (NY: LLY)
79.06 USD  -0.69 (-0.87%)
Official Closing Price  /  Updated: 8:04 PM EDT, Apr 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 5,424,115
Open 79.64
Bid (Size) 78.61 (300)
Ask (Size) 88.00 (100)
Prev. Close 79.75
Today's Range 78.82 - 79.91
52wk Range 73.69 - 89.09
Shares Outstanding 1,092,700,369
Dividend Yield 2.68%
Performance
YTD
-6.64%
-6.64%
1 Month
+1.05%
+1.05%
3 Month
-7.52%
-7.52%
6 Month
-9.37%
-9.37%
1 Year
-3.51%
-3.51%
Top News
More News
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Significant improvement in primary endpoint of progression-free survival previously reported; Improvement in objective response rate observed; Positive trend in overall survival did not reach... Read More
from PR Newswire
Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine
Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology (AAN)... Read More
from PR Newswire
More News
Read More
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
from PR Newswire
Quotidian Technical Highlights on Selected Drug Makers Stocks -- AbbVie, Biostar Pharma, Bristol-Myers Squibb, and Eli Lilly
from PR Newswire
BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study
category companyNews
from Reuters: Company News
FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug
category companyNews
from Reuters: Company News
Amgen's Aimovig halved migraine days in 30 pct of trial patients
category companyNews
from Reuters: Company News
VYM, QCOM, CAT, LLY: Large Outflows Detected at ETF
category ETFs
from ETF Channel
Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
category GSK , LLY
from Motley Fool
Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More
category LLY , CAT , TSLA , and 19 more.
from Benzinga
3 Biotech Stocks With Major Catalysts Incoming
category TGTX , INCY , LLY , and 2 more.
from Motley Fool
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial